Transrectal prostate biopsy-associated prophylaxis and infectious complications: Report of a query to the emerging infections network of the Infectious Diseases Society of America

Open Forum Infectious Diseases

Volumn 2, Issue 1, 2015, Pages

  Johnson, James R ^a,b   Polgreen, Philip M ^c   Beekmann, Susan E ^c  

^a VETERANS AFFAIRS MEDICAL CENTER   (United States)

^b UNIVERSITY OF MINNESOTA   (United States)

^c UNIVERSITY OF IOWA   (United States)

Author keywords

Antimicrobial resistance; Infection; Prophylaxis; Prostate biopsy; Sepsis

Indexed keywords

AMINOGLYCOSIDE; AZTREONAM; CARBAPENEM; CEPHALOSPORIN; CIPROFLOXACIN; COTRIMOXAZOLE; IMIPENEM; QUINOLINE DERIVED ANTIINFECTIVE AGENT;

ARTICLE; ENDOCARDITIS; EPIDURAL ABSCESS; HEALTH SURVEY; HUMAN; HUMAN TISSUE; INFECTION CONTROL; MAJOR CLINICAL STUDY; MALE; OSTEOMYELITIS; PRIORITY JOURNAL; PROSTATE BIOPSY; SEPSIS;

EID: 84978328500     PISSN: None     EISSN: 23288957     Source Type: Journal    
DOI: 10.1093/ofid/ofv002     Document Type: Article

References (35)

1. Williamson DA, Roberts SA, Paterson DL, et al. Escherichia coli bloodstream infection after transrectal ultrasound-guided prostate biopsy: implications of fluoroquinolone-resistant sequence type 131 as a major causative pathogen. Clin Infect Dis 2012; 54:1406-12.
2. Nam RK, Saskin R, Lee Y, et al. Increasing hospital admission rates for urological complications after transrectal ultrasound guided prostate biopsy. J Urol 2010; 183:963-8.
3. Loeb S, Carter HB, Berndt SI, et al. Complications after prostate biopsy: data from SEER-Medicare. J Urol 2011; 186:1830-4.
4. Batura D, Rao GG. The national burden of infections after prostate biopsy in England andWales: a wake-up call for better prevention. J Antimicrob Agents Chemother 2013; 68:247-9.
5. Ho HS, Ng LG, Tan YH, et al. Intramuscular gentamicin improves the efficacy of ciprofloxacin as an antibiotic prophylaxis for transrectal prostate biopsy. Ann Acad Med Singapore 2009; 38:212-6.
6. Batura D, Rao GG, Bo Nielsen P, et al. Adding amikacin to fluoroquinolone-based antimicrobial prophylaxis reduces prostate biopsy infection rates. BJU Int 2011; 107:760-4.
7. Adibi M, Hornberger B, Bhat D, et al. Reduction in hospital admission rates due to post-prostate biopsy infections after augmenting standard antibiotic prophylaxis. J Urol 2013; 189:535-40.
8. Lorber G, Benenson S, Rosenberg S, et al. A single dose of 240 mg gentamicin during transrectal prostate biopsy significantly reduces septic complications. Urology 2013; 82:998-1003.
9. Losco G, Studd R, Blackmore T. Ertapenem prophylaxis reduces sepsis after transrectal biopsy of the prostate. BJU Int 2014; 113(Supplement 2):69-72.
10. Kehinde EO, Al-Maghrebi M, Sheikh M, et al. Combined ciprofloxacin and amikacin prophylaxis in the prevention of septicemia after transrectal ultrasound guided biopsy of the prostate. J Urol 2014; 189:911-5.
11. Duplessis CA, Bavaro M, Simons MP, et al. Rectal cultures before transrectal ultrasound-guided prostate biopsy reduce post-prostatic biopsy infection rates. Urology 2012; 79:556-63.
12. Suwantarat N, Dumford DM III, Ponce-Terashima R, et al. Modification of antimicrobial prophylaxis based on rectal culture results to prevent fluoroquinolone-resistant Escherichia coli infections after prostate biopsy. Infect Control Hosp Epidemiol 2013; 34:973-6.
13. Taylor AK, Zembower RT, Nadler RB, et al. Targeted antimicrobial prophylaxis using rectal swab cultures in men undergoing transrectal ultrasound guided prostate biopsy is associated with reduced incidence of postoperative infectious complications and cost of care. J Urol 2012; 187:1275-9.
14. Dai J, Leone A, Mermel L, et al. Antimicrobial prophylaxis for prostate biopsy and risk of postprocedure infection: a cohort study. J Urol 2014; 85:8-14.
15. Bratzler DW, Dellinger EP, Olsen KM, et al. Clinical practice guidelines for antimicrobial prophylaxis in surgery. Am J Health Syst Pharm 2013; 70:195-283.
16. American Urological Association. Best practice policy statement on urologic surgery antimicrobial prophylaxis. Available at: https://www.auanet.org/education/guidelines/antimicrobial-prophylaxis.cfm. Accessed 6 November 2014.
17. Pillai SK, Beekmann SE, Santibanez S, et al. The Infectious Diseases Society of America emerging infections network: bridging the gap between clinical infectious diseases and public health. Clin Infect Dis 2014; 58:991-6.
18. US Census Bureau. Census Bureau Regions and Divisions with State FIPS Codes. https://www.census.gov/geo/maps-data/maps/pdfs/reference/us_regdiv.pdf. Accessed 27 October 2014.
19. Zaytoun OM, Vargo EH, Rajan R, et al. Emergence of rluoroquinoloneresistant Escherichia coli as cause of postprostate biopsy infection: implications for prophylaxis and treatment. Urology 2011; 77:1035-42.
20. Pollukcu H, Tasbakan M, Ripahi OR, et al. Fosfomycin in the treatment of extended spectrum beta-lactamase-producing Escherichia coli-related lower urinary tract infections. Int J Antimicrob Agents 2007; 29:62-5.
21. Johnson JR, Drawz SM, Porter S, et al. Susceptibility to alternative oral antimicrobial agents in relation to sequence type ST131 status and coresistance phenotype among recent Escherichia coli isolates from U.S. veterans. Antimicrob Agents Chemother 2013; 57:4856-60.
22. Drawz SM, Johnson JR. Pokes, pathogens, and primum non nocere: prudent prophylaxis protocols for prostate biopsy. Infect Control Hosp Epidemiol 2013; 34:977-9.
23. Roberts MJ, Williamson DA, Hadway P, et al. Baseline prevalence of antimicrobial resistance and subsequent infection following prostate biopsy using empirical or altered prophylaxis: a bias-adjusted meta-analysis. Int J Antimicrob Agents 2014; 43:301-9.
24. Zani EL, Clark OA, Rodrigues Netto N Jr. Antibiotic prophylaxis for transrectal prostate biopsy. Cochrane Database Syst Rev 2011; doi:10.1002/146518.CD006576.pub2.
25. Charalabopoulos K, Krachalios G, Baltogiannis C, et al. Penetration of anatimicrobial agents into the prostate. Chemother 2003; 49:269-79.
26. Lipsky BA, Byren I, Hoey CT. Treatment of bacterial prostatitis. Clin Infect Dis 2010; 50:1641-52.
27. Assimacopoulos A, Johnston B, Clabots C, et al. Post-prostate biopsy infection with Escherichia coli ST131 leading to epididymo-orchitis and meningitis caused by Gram-negative bacilli. J Clin Microbiol 2012; 50:4157-9.
28. Tufan ZK, Bulut C, Yazan T, et al. A life-threatening Escherichia coli meningitis after prostate biopsy. Urol J 2011; 8:69-71.
29. Arain FA, Williams BD, Lick SD, et al. Echocardiographic, histopathologic, and surgical findings in Staphylococcus lugdunensis mitral valve endocarditis after prostate biopsy. Circulation 2013; 128:e204-6.
30. Fordyce CB, Leather RA, Partlow E, et al. Complete heart block associated with tricuspid valve endocarditis due to extended spectrum β-lactamase-producing Escherichia coli. Can J Cardiol 2011; 27: e17-20.
31. Kaya M, Kösemehmetoglu K, Yildirim C, et al. Spondylodiscitis as a spinal complication of transrectal ultrasound-guided needle biopsy of the prostate. Spine 2012; 37:e870-2.
32. Fradet V, McCormack M, Perrotte P, et al. An epidural abscess following transrectal ultrasound-guided biopsies of the prostate. Can J Urol 2005; 12:2899-900.
33. Owens RC, Johnson JR, Stogstill P, et al. Community transmission in the United States of a CTX-M-15-producing sequence type ST131 Escherichia coli strain resulting in death. J Clin Microbiol 2011; 49:3406-8.
34. Ender PT, Gajanana D, Johnston B, et al. Transmission of extendedspectrum beta-lactamase-producing Escherichia coli (sequence type ST131) between a father and daughter resulting in septic shock and emphysematous pyelonephritis. J Clin Microbiol 2009; 47:3780-2.
35. Moyer VA. Screening for prostate cancer: U.S. Preventive Services Task Force recommendation statement. Ann Intern Med 2012; 157:120-34.